4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Kodiak Sciences Inc. (KOD) operates in the Biotechnology industry and is headquartered in Palo Alto, United States with about 130 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, KOD reported $0M in revenue and ($230M) in net income.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($234M) | ($187M) | ($277M) | ($341M) |
| Net Income | ($230M) | ($176M) | ($260M) | ($334M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($60M) | ($58M) | ($62M) | ($56M) | ($59M) | — |
| Net Income | ($58M) | ($57M) | ($62M) | ($54M) | ($58M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $352M | $336M | $479M | $667M | — |
| Total Liabilities | $194M | $185M | $214M | $230M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive KOD viewer.
About TickerBase · Data methodology & sources